EARS - Auris Medical Holding AG

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.3095
+0.0195 (+6.72%)
As of 3:22PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.2900
Open0.2870
Bid0.3020 x 800
Ask0.3027 x 1300
Day's Range0.2750 - 0.3300
52 Week Range0.2300 - 9.5000
Volume1,012,081
Avg. Volume1,375,201
Market Cap7.448M
Beta0.21
PE Ratio (TTM)N/A
EPS (TTM)-2.9710
Earnings DateNov 8, 2017 - Nov 13, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Trade prices are not sourced from all markets
  • GlobeNewswire19 days ago

    Auris Medical Receives FDA Guidance at Type C Meeting for AM-111 in the Treatment of Sudden Sensorineural Hearing Loss

    Auris Medical Holding AG (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental disorders supportive care, announced today feedback from a Type C meeting with the U.S. Food and Drug Administration (FDA) related to the development plan and regulatory pathway for AM-111, its investigational treatment for sudden sensorineural hearing loss. The Type C meeting had been requested by the Company following the results of the HEALOS phase 3 trial. The results showed, based on a post-hoc analysis, a clinically meaningful and nominally significant improvement in hearing for the AM-111 0.4 mg/mL group compared to placebo in the subpopulation of patients with acute profound hearing loss.

  • Associated Presslast month

    Auris: 2Q Earnings Snapshot

    On a per-share basis, the Zug, Switzerland-based company said it had a loss of 51 cents. The company's shares closed at 28 cents. A year ago, they were trading at $7.70. _____ This story was generated ...

  • GlobeNewswirelast month

    Auris Medical Reports Second Quarter 2018 Financial Results and Provides Business Update

    Dosing in second Phase 1 clinical trial with intranasal betahistine nearing completion Approaching important interactions with regulatory agencies Progressing with strategic repositioning of Company Zug, ...

  • GlobeNewswirelast month

    Auris Medical to Report Second Quarter 2018 Financial Results and Provide Business and Update on Wednesday, August 15, 2018

    Zug, Switzerland, August 09, 2018- Auris Medical Holding AG, a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental health supportive ...

  • ACCESSWIRE2 months ago

    Complimentary Technical Snapshots on OHR Pharma and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 13, 2018 / If you want a free Stock Review on OHRP sign up now at www.wallstequities.com/registration. For today, WallStEquities.com observes Auris Medical Holding AG (EARS), NewLink Genetics Corp. (NLNK), OHR Pharmaceutical Inc. (OHRP), and Omeros Corp. (OMER). The industry includes the manufacturing and marketing of drugs as a result of direct research and development.

  • GlobeNewswire2 months ago

    Auris Medical Prices $7 Million Public Offering

    Zug, Switzerland- July 12, 2018- Auris Medical Holding AG, a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental health supportive ...

  • GlobeNewswire3 months ago

    Auris Medical Announces Publication Confirming Dose-Dependent Effects of Betahistine and Relationship to Bioavailability in Cat Model of Acute Vertigo

    Auris Medical Holding AG (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental health supportive care, today announced the publication of an article confirming dose-dependent effects of betahistine and their relationship to bioavailability in a cat model of surgery-induced acute vertigo. The article presents the outcomes of a study with betahistine in a previously established model of acute loss of vestibular function in cats following the unilateral sectioning of the vestibular nerve (neurectomy).

  • ACCESSWIRE3 months ago

    Free Technical Reports on Arrowhead Pharma and Three Additional Biotech Equities

    On Tuesday, June 12, 2018, the NASDAQ Composite and the S&P 500 edged 0.57% and 0.17% higher, respectively at the closing bell, while the Dow Jones Industrial Average stayed bearish, finishing marginally lower by 0.01%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), Atara Biotherapeutics Inc. (NASDAQ: ATRA), Athersys Inc. (NASDAQ: ATHX), and Auris Medical Holding AG (NASDAQ: EARS).

  • What Are The Drivers Of Auris Medical Holding AG’s (NASDAQ:EARS) Risks?
    Simply Wall St.3 months ago

    What Are The Drivers Of Auris Medical Holding AG’s (NASDAQ:EARS) Risks?

    For Auris Medical Holding AG’s (NASDAQ:EARS) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. EARS isRead More...

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of EARS earnings conference call or presentation 15-May-18 12:00pm GMT

    Q1 2018 Auris Medical Holding AG Earnings Call

  • Associated Press4 months ago

    Auris: 1Q Earnings Snapshot

    On a per-share basis, the Zug, Switzerland-based company said it had a loss of 32 cents. The company's shares closed at $1.70. A year ago, they were trading at $7.02. _____ This story was generated by ...

  • ACCESSWIRE4 months ago

    Wired News – Auris Medical Reported Publication Related to AM-111 in Peer-Reviewed Scientific Journal Hearing Research

    LONDON, UK / ACCESSWIRE / May 08, 2018 / If you want access to our free research report on Auris Medical Holding AG (NASDAQ: EARS), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EARS as the Company's latest news hit the wire. On May 04, 2018, the Switzerland-based biopharmaceutical Company announced that the article reviewing the mechanism of action, pharmacokinetics and therapeutic applications of AM-111, the Company's investigational treatment for acute inner ear hearing loss, was published in Hearing Research, one of the leading journals in the otorhinolaryngology field. The peer-reviewed article "Preclinical and clinical otoprotective applications of cell-penetrating peptide D-JNKI-1 (AM-111)" was published.

  • Benzinga4 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Starbucks Corporation (NASDAQ: SBUX ) stock gained ...

  • ACCESSWIRE6 months ago

    Blog Exposure - Actinium Announces Collaboration with Astellas Pharma

    Stock Monitor: Auris Medical Holding Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 02, 2018 / Active-Investors.com has just released a free research report on Actinium Pharma, Inc. (NYSE: ATNM ...

  • Associated Press6 months ago

    Auris reports 4Q loss

    The Zug, Switzerland-based company said it had a loss of $1.01 per share. For the year, the company reported that its loss narrowed to $24.8 million, or $5.69 per share. The company's shares closed at ...

  • Benzinga6 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Advanced Micro Devices, Inc. (NASDAQ: AMD ) stock ...